Cardiff Oncology Inc. (NASDAQ: CRDF)
$2.61
+0.0950 ( +3.79% ) 182.1K
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Market Data
Open
$2.61
Previous close
$2.51
Volume
182.1K
Market cap
$115.20M
Day range
$2.53 - $2.65
52 week range
$0.94 - $6.42
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
8-k | 8K-related | 14 | Jun 20, 2024 |
8-k | 8K-related | 15 | Jun 03, 2024 |
10-q | Quarterly Reports | 48 | May 02, 2024 |
8-k | 8K-related | 16 | May 02, 2024 |